Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer

Table 1 Infusion area in interventional approaches

Infusion area	Gastroesophageal junction obstruction, n	Pyloric obstruction, n	Anastomosis obstruction, n
Left gastric artery	13	5	1
Right gastric artery	1	3	0
Right gastroepiploic artery	0	13	2
Left gastric artery and right gastroepiploic artery	5	0	0
Right gastric artery and right gastroepiploic artery	0	23	0
Left gastric artery and right gastric artery	1	1	0
Others	71	62	12

¹Including left gastroepiploic artery, left Inferior phrenic artery, superior mesenteric artery branch.

²Including common hepatic artery, coeliac trunk artery.

Table 2 Tumor radiologic response evaluated by Response Evaluation Criteria In Solid Tumors criteria

	After the first cGAIC, n (%)	After the second cGAIC, n (%)	After the third cGAIC, n (%)	After the fourth cGAIC, n (%)	After the fifth cGAIC, n (%)	After the sixth cGAIC, n (%)
CR	0 (0)	1 (3.7)	4 (21.1)	0 (0)	0 (0)	0 (0)
PR	25 (86.2)	23 (85.2)	12 (63.2)	3 (100)	2 (100)	2 (100)
SD	4 (13.8)	3 (11.1)	3 (15.8)	0 (0)	0 (0)	0 (0)
PD	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Total	29	27	19	3	2	2

Date in parentheses are percentages. Total = number of patients finished the treatments. cGAIC: Continuous gastric artery infusion chemotherapy; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 3 Comparison of Stooler’s Dysphagia Score

	Before cGAIC, n	After cGAIC, n	P value
Stooler’s Dysphagia Score			< 0.001
I	0	6
II	0	14
III	22	8
IV	7	1

Stooler’s Dysphagia Score reflected the degree of digestive obstruction. I: Semi dry food; II: Soft food; III: Fluid; IV: Completely unable to feed orally; cGAIC: Continuous gastric artery infusion chemotherapy.

Table 4 Univariate and Multivariate survival analysis for overall survival

Variables	n (%)	Univariate survival analysis			Multivariate survival analysis
		HR	95%CI	P value	HR	95%CI	P value
Gender
Male	20 (69)	1.53	0.49-4.85	0.466
Female	9 (31)	1
Intravenous chemotherapy history
No	22 (76)	0.30	0.11-0.83	0.020
Yes	7 (24)	1
Gastric cancer surgery history
No	27 (93)	0.51	0.12-2.29	0.381
Yes	2 (7)	1
Pathology
Squamous cell carcinoma	2 (7)	9.24	1.62-52.69	0.012
Signet ring cell carcinoma	8 (27)	0.66	0.18-2.44	0.535
Adenocarcinoma	19 (66)	1
Tumor invasion
≤ T4a	19 (66)	0.48	0.17-1.32	0.153
T4b	10 (34)	1
Metastasis
No	9 (31)	0.63	0.20-1.98	0.425
Yes	20 (69)
Obstructive location
Gastroesophageal junction	6 (21)	1.21	2.24-6.10	0.816
Pylorus	21 (72)	0.35	0.07-1.68	0.188
Anastomosis	2 (7)	1
Stooler’s Dysphagia Score
III	22 (76)	0.34	0.11-1.02	0.055
IV	7 (24)	1
Relieve digestive obstruction
No	7 (24)	2.55	0.84-7.72	0.098
Yes	22 (76)
Radical resection after cGAIC
No	16 (55)	9.56	2.11-43.44	0.003	8.48	1.27-56.51	0.027
Yes	13 (45)
Intravenous chemotherapy after cGAIC
No	10(34)	6.20	2.14-18.00	0.001	8.61	1.42-52.17	0.019
Yes	19(66)
Immunotherapy after cGAIC
No	18(62)	4.12	0.93-18.28	0.063	13.09	1.64-104-12	0.015
Yes	11(38)

HR: Hazard ratio; CI: Confidence interval; cGAIC: Continuous gastric artery infusion chemotherapy.

Table 5 Adverse events after constant gastric artery infusion chemotherapy

Adverse events	Grade 1, n (%)	Grade 2, n (%)
Nausea and vomiting	4 (13.8)	2 (6.9)
Abdominal pain	3 (10.3)	1 (3.4)
Gastrointestinal hemorrhage	0 (0)	0 (0)
Neutropenia	2 (6.9)	2 (6.9)
Anemia	1 (3.4)	0 (0)
Thrombocytopenia	2 (6.9)	2 (6.9)
Paresthesia	1 (3.4)	1 (4.3)
Liver enzyme increased	1 (3.4)	3 (10.3)

Common Terminology Criteria for Adverse Events Version 5.0. Date in parentheses are percentages.